Nerlynx (Neratinib)

Neratinib, the active ingredient in Nerlynx, is a tyrosine kinase inhibitor presented as a 240 mg tablet for oral use. It is indicated for HER2‑positive breast cancer, both as extended adjuvant therapy after trastuzumab in early‑stage disease and for treatment of HER2‑positive metastatic breast cancer.

GNH USA supplies Nerlynx as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide. Our distribution network ensures reliable access to the product across Europe, Asia and the Americas, complying with local regulatory requirements.

Neratinib is used in the HER2‑positive breast cancer pathway to inhibit tumor growth. - Early‑stage HER2‑positive breast cancer: Provides extended adjuvant therapy after trastuzumab to lower recurrence risk. - Metastatic HER2‑positive breast cancer: Offers systemic treatment to slow disease progression. - HER2‑positive disease after prior HER2‑targeted therapy: Supplies an oral HER2 blockade option for patients who have received trastuzumab.

Neratinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Diarrhea: frequent, may be severe. - Nausea: mild to moderate. - Fatigue: general tiredness. - Rash: skin irritation.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiac dysfunction: reduced left ventricular ejection fraction. - Severe diarrhea leading to dehydration.

When prescribing Neratinib, clinicians should observe several precautionary measures to minimize risk. - Monitor liver function: check baseline and periodic hepatic enzymes. - Assess cardiac status: evaluate left ventricular function before and during therapy. - Manage diarrhea proactively: initiate antidiarrheal agents at first sign. - Avoid use in pregnancy: drug is contraindicated; ensure effective contraception. - Adjust for drug interactions: review concomitant medications that affect CYP3A4. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Neratinib can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce neratinib exposure. - Antacids containing aluminum or magnesium: can decrease absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase neratinib levels. - Proton pump inhibitors: may modestly affect gastric pH and drug absorption. - Anticoagulants (e.g., warfarin): monitor INR as neratinib may affect metabolism.